Evidence mapPaperPMID 41752015Full record

ReviewInternational journal of molecular sciences2026

Targeting the Biology of Aging in Cerebrovascular Disease: Inflammation, Metabolism, Senescence, and Regeneration.

Daniela Glavan, Thorsten R Doeppner, Mihaela Abuzan, Dirk M Hermann, Bogdan Capitanescu, Denisa Greta Olaru, Aurel Popa-Wagner

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Daniela GlavanDepartment of Neurology, University Medical Center Göttingen, 37075 Göttingen, Germany.
Thorsten R DoeppnerDepartment of Neurology, University Medical Center Göttingen, 37075 Göttingen, Germany.
Mihaela AbuzanExperimental Research Center for Normal and Pathological Aging (ARES), University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Dirk M HermannExperimental Research Center for Normal and Pathological Aging (ARES), University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Bogdan CapitanescuExperimental Research Center for Normal and Pathological Aging (ARES), University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Denisa Greta OlaruExperimental Research Center for Normal and Pathological Aging (ARES), University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.
Aurel Popa-WagnerClinic of Psychiatry, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.ORCID 0000-0003-4574-8605

Funding

European Union Brussel 760058 to DMH, and by the UEFISCDI Project No. PN-III-P4-ID-PCE-2020-059 to APW
6 · The paper itself

Abstract

Aging is the strongest independent risk factor for cerebrovascular diseases, profoundly influencing vascular structure, immune responses, and regenerative capacity of the brain. Traditional therapeutic strategies, largely developed in younger populations, often show reduced efficacy and increased risk in elderly patients, underscoring the need for age-adapted interventions. Advances in the understanding of cerebrovascular aging have revealed key mechanisms such as vascular senescence, chronic low-grade inflammation, blood-brain barrier dysfunction, mitochondrial impairment, and circadian dysregulation as central drivers of disease progression and poor recovery. This narrative review summarizes emerging therapeutic strategies targeting the molecular and cellular hallmarks of aging-related cerebrovascular disease. These include immunomodulatory and anti-inflammatory approaches, senescence-targeted therapies, stem cell and extracellular vesicle-based regenerative strategies, RNA-based interventions, and metabolic and mitochondrial modulation. Particular emphasis is placed on therapies aimed at restoring neurovascular unit integrity and promoting brain repair in the aged microenvironment. Additionally, this review highlights the growing role of chronobiology and precision medicine, integrating biomarkers and multi-omics approaches to tailor treatments for elderly patients. Collectively, these emerging therapies represent a paradigm shift from symptom-oriented management toward mechanism-based and personalized interventions. Addressing age-specific pathophysiology will be critical for improving outcomes in cerebrovascular diseases in the aging population and for translating experimental advances into effective clinical therapies.

Indexed as

AgingCellular SenescenceCerebrovascular DisordersInflammationRegenerationAnimalsHumansageingcerebrovascular diseasesinflammationmetabolismregeneration

Identifiers

PMID41752015
PMCPMC12941123

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.